Regeneron, Sanofi presents results from DISCOVER Phase 4 trial of Dupixent

Regeneron Pharmaceuticals (REGN) and Sanofi (SNY) presented results from the DISCOVER Phase 4, single-arm, open-label trial assessing Dupixent in adults and adolescents with moderate-to-severe atopic dermatitis with skin of color. These are the first clinical trial results for Dupixent in a large population of patients with darker skin tones. The results, along with the Dupixent Phase 3 trials, demonstrated patients taking Dupixent experienced improvements in signs and symptoms of atopic dermatitis from baseline across many skin tones. The data were shared in an oral presentation at the 2025 Revolutionizing Atopic Dermatitis, RAD, Conference. In the trial, 120 patients with atopic dermatitis and skin of color were treated with Dupixent every two weeks using a weight-based dosing regimen. At 24 weeks: 76% achieved a greater than or equal to75% improvement in overall disease severity, the primary endpoint. Improvements were seen by some patients as early as two weeks. 53% achieved clinically meaningful improvement in itch. Improvements were seen by some patients as early as two weeks. Patients experienced a 53% reduction from baseline in post-inflammatory hyperpigmentation, dropping from 5.1 points to 2.4 points. 18% were very or extremely bothered by dry skin vs. 78% at baseline, based on patient reporting.
Confident Investing Starts Here:

Try Our AI Features

Explore what Daily8 AI can do for you:

Learn with AIFact CheckingText to SpeechAI Summary

Related Articles

Yahoo

2 days ago

• Yahoo

Sanofi (ENXTPA:SAN) Gains FDA Approval For Dupixent To Address Rare Skin Disease

Sanofi experienced a 4% decline over the past week despite a largely unchanged market. The recent events, including the FDA approval of Dupixent for a rare skin condition and the signing of a memorandum with the Department of Health - Abu Dhabi, signal positive developments for its collaborative efforts with Regeneron and internal growth strategies. Although these announcements are significant, they were not sufficient to counteract the broader move, which might have been influenced by other factors specific to Sanofi, such as its recent €1.5 billion notes offering aimed at supporting corporate purposes. Buy, Hold or Sell Sanofi? View our complete analysis and fair value estimate and you decide. Explore 26 top quantum computing companies leading the revolution in next-gen technology and shaping the future with breakthroughs in quantum algorithms, superconducting qubits, and cutting-edge research. The recent developments for Sanofi, including FDA approval of Dupixent for a rare skin condition and the memorandum with the Department of Health - Abu Dhabi, highlight efforts to enhance revenue growth through expanded market reach and innovation. Despite these positive updates, Sanofi shares experienced a 4% decline over the past week, influenced by factors such as the recent €1.5 billion notes offering. Over a longer-term period, Sanofi achieved a total shareholder return of 11.29% over five years. Comparatively, over the past year, Sanofi's performance matched the French Pharmaceuticals industry, which reported a similar decline of 5.9%. In contrast, the broader French Market fared slightly better, returning 2.2%. The recent news related to Dupixent and international partnerships could potentially boost Sanofi's revenue and earnings forecasts, providing a catalyst for future growth given the innovative pipeline and market penetration opportunities. Considering the current share price of €95.9 and the analyst consensus price target of €117.7, there is potential for an 18.5% increase, according to market projections. These developments need to be weighed against existing market conditions and company fundamentals, as analysts remain divided on future earnings prospects and valuations. Click here to discover the nuances of Sanofi with our detailed analytical financial health report. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include ENXTPA:SAN. This article was originally published by Simply Wall St. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@

Boston Globe

3 days ago

• Boston Globe

Edward Anders, who duped Nazis and illuminated the cosmos, dies at 98

Settling in New York City, Edward enrolled at Columbia University and studied chemistry. One day, his professor — a curator at the American Museum of Natural History — brought a handful of meteorite rocks to pass around in class. Get Starting Point A guide through the most important stories of the morning, delivered Monday through Friday. Enter Email Sign Up 'I found them tremendously exciting,' Dr. Anders said in a 2001 interview with the journal Meteoritics & Planetary Science. 'I would even use the word romantic. Here were samples from far beyond the Earth's orbit, older than any rock on Earth, and you can get your hands on them, and even do respectable research on them.' Advertisement Dr. Anders's research turned out to be more than merely respectable. At the University of Chicago, his academic home for more than 30 years beginning in 1955, he conducted a series of groundbreaking studies into the early history of the solar system. He demonstrated that meteorites were fragments from asteroids and not, as was believed at the time, debris from the moon or comets. He quantified the elements of the solar system in a journal article that has been cited more than 14,000 times. And he uncovered evidence of the global wildfires that helped lead to the dinosaurs' extinction. Advertisement 'I find it hard to conceive of our science without Ed Anders,' Michael J. Drake, a planetary science professor at the University of Arizona, said in a speech in 1990 in which he presented Dr. Anders with the V.M. Goldschmidt Award, the top honor of the Geochemical Society. Dr. Anders spoke about the cosmos whimsically, with a sense of curiosity and awe. In an interview with Discover magazine in 1991, he marveled at the rather mind-bending notion that everything about Earth — on it, in it, under it, around it — was unoriginal. 'The material in the solar system is secondhand,' he said. 'All of it originally was older than the solar system, but most of it has been reprocessed.' He called meteorites 'the poor man's space probe,' because they deliver pieces of asteroids that scientists are able to study without traveling to outer space. The mysteries in the stardust they carry — of diamonds, graphite and silicon carbide — are never-ending, like the stars. 'What was the raw material of the solar system?' he asked in the Discover interview. 'Where did it come from? What were the nuclear and chemical processes in the parent stars? And how was this material altered in the early solar system?' Dr. Anders spent his life trying to answer these celestial, seemingly impossible questions, even as painful, seemingly inexplicable ones about his childhood haunted him. Advertisement Edward Alperovitch was born June 21, 1926, in Liepaja and changed his surname to Anders when he became a naturalized US citizen in 1955. His father, Adolph Alperovitch, was a merchant. His mother, Erica (Sheftelovitch-Meiran) Alperovitch, was a file clerk. When Edward was 14 years old, Soviet forces occupied Latvia, and his parents were forced to rent rooms in their apartment to Russian border guards. In June 1941, the Soviets began mass deportations to Russia. Edward's family was on the deportation list and received orders to pack their belongings. One of their border-guard tenants, feeling sympathy for the family, removed them from the list. 'For the moment, we were saved,' Dr. Anders recalled in 1997 in an oral history interview for the United States Holocaust Memorial Museum in Washington. After Germany invaded the Soviet Union and occupied Latvia, Jews faced restrictions on their movements and on their ability to practice their faith. Several hundred were massacred in a local park during a Nazi rampage. Edward and his family thought their days were numbered. Then his father had an idea: Concoct a story about how his wife was not the biological child of Jewish parents, but rather an Aryan found on their doorstep in a basket with a note saying that she had been baptized. That made Edward and his brother half-Jews — 'only second class rather than total outcasts,' he said in the museum oral history. 'It was an absolutely crazy story for us to start,' he added, 'extremely audacious.' It worked, but not for Edward's father, who had essentially sacrificed himself as part of the plan. He hid in the family's apartment but was discovered in November 1941 and arrested. A week later, a firing squad executed him. Advertisement The 'half-Jew' ruse continued for several years, and it ultimately spared Edward, along with his mother and brother, from a trip to a Nazi death camp. 'If we had any inkling that the war was going to last another four years, we never would have tried this plan, because this is a lie that simply couldn't go on for four years,' he said. 'We were just playing for time. Well, it worked, all right.' Edward never finished high school, nor did he receive a bachelor's degree. After the war, he studied chemistry at a school in Munich affiliated with the United Nations. He later taught himself chemistry as a lab assistant at the University of Munich. After emigrating to the United States, he earned a doctorate from Columbia in 1954. Throughout his career as a cosmochemist, Dr. Anders rarely, if ever, spoke about his childhood. 'You file it away in the proper place,' he said. 'You know where to find it when you need it. The file drawers don't pop open spontaneously.' But after retiring, he began to revisit his memories in greater detail. He wrote a memoir, 'Amidst Latvians During the Holocaust' (2011), and created a database of the more than 7,000 Jews who were alive in Liepaja when the Germans rolled in. 'Most Holocaust victims have become nameless statistics,' he wrote in the journal Holocaust and Genocide Studies. 'That would have pleased Hitler.' Using government documents, directories, diaries and other materials he found in archives, Anders cataloged what happened to thousands of Jews in his town. He gave them back their names. Advertisement 'Edward always saw himself as a bridge builder between past and present, between Jews and non-Jews, between the continents,' Uwe Neumärker, a historian who helped arrange for Anders' memoir to be published in German, said by email. Dr. Anders married Joan Fleming in 1955. She died in 2019. In addition to his son, George, he is survived by a daughter, Nanci Schiman; five grandchildren; and three great-grandchildren. His brother, Georg, died of diphtheria in 1944. Dr. Anders was raised Jewish but described himself as agnostic. 'In a way, peering into the solar system had an almost a spiritual component for him,' his son said in an interview. 'This was the creation story, and the creation story was pretty exciting and pretty amazing and pretty mysterious.' This article originally appeared in

Yahoo

3 days ago

• Yahoo

London Biotechnology Show 2025: Novo Nordisk harnesses AI/ML to accelerate drug development landscape

Many biotechnology companies are navigating the various obstacles prevalent within the pharmaceutical industry with the implementation of artificial intelligence (AI) and machine learning (ML) technologies to optimise and streamline processes within the drug development landscape, according to speakers from the London biotechnology conference in London, UK, on 18-19 June 2025. In recent years, the pharmaceutical industry has exhibited a significant shift into digitalisation, with AI pushing for innovation across the entire drug development value chain, from accelerating drug discovery to optimising clinical trial design to ultimately improve patient outcomes. Novo Nordisk has taken initiatives to accelerate target discovery by implementing AI/ML technologies into genetic and human-centric in vitro models. Given the significant costs associated with drug discovery and development, achieving a successful drug candidate remains a major challenge. This complex process involves different processes such as target identification and validation, lead optimisation, and lengthy clinical trials. According to one of Novo Nordisk's speakers at the London Biotechnology conference, the company aims to utilise human data input, such as genetics, samples, and multiomics from a variety of diverse patient populations, into its target discovery engine. The AI-driven engine utilises data mining and analyses linking specific diseases to novel targets to ultimately increase the number of new targets aimed to reach the first human dose. In addition, Novo Nordisk has implemented cell image foundational models driven by deep learning to increase screening throughput derived from extensive sets of genomic data. The usage of AI and deep learning tools within the virtual assay enables large image datasets of cells to be translated into text, allowing effective mapping of the various cells by their morphology, enabling researchers to gain an understanding and effectively predict the characteristics of the cells. The implementation of AI-driven technologies has the potential to streamline many aspects of the drug development value chain, from enabling standardisation of datasets across functionalities to accelerating in vitro and in silico models and tools. As a result, pharmaceutical organisations can scale their methodologies whilst simultaneously increasing output to ultimately improve patient outcomes. "London Biotechnology Show 2025: Novo Nordisk harnesses AI/ML to accelerate drug development landscape" was originally created and published by Pharmaceutical Technology, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Sign in to access your portfolio